CYDX (Cyduct Diagnostics) FCF Yield %: 0.00 (As of Jun. 30, 2026)


What is Cyduct Diagnostics FCF Yield %?

Cyduct Diagnostics CYDX +4.22% FCF Yield % is 0.00 as of Jun. 30, 2026.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Cyduct Diagnostics's Trailing 12-Month Free Cash Flow is $0.00 Mil, and Market Cap is $2.20 Mil. Therefore, Cyduct Diagnostics's FCF Yield % for today is 0.00%.

The historical rank and industry rank for Cyduct Diagnostics's FCF Yield % or its related term are showing as below:


CYDX's FCF Yield % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: -0.385
* Ranked among companies with meaningful FCF Yield % only.

Cyduct Diagnostics's FCF Margin % for the quarter that ended in . 20 was 0.00%.

Cyduct Diagnostics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Cyduct Diagnostics FCF Yield % Related Terms

Cyduct Diagnostics FCF Yield % Historical Data

* Premium members only.

The historical data trend for Cyduct Diagnostics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyduct Diagnostics FCF Yield % Chart

Cyduct Diagnostics Annual Data
Trend
FCF Yield %

Cyduct Diagnostics Quarterly Data
FCF Yield %

CYDX vs SECI, QTXB, ASNB: FCF Yield % Comparison

For the Medical Devices subindustry, Cyduct Diagnostics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cyduct Diagnostics FCF Yield % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cyduct Diagnostics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Cyduct Diagnostics's FCF Yield % falls into.


Cyduct Diagnostics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Cyduct Diagnostics's FCF Yield % for the fiscal year that ended in . 20 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
= /
=N/A%

Cyduct Diagnostics's annualized FCF Yield % for the quarter that ended in . 20 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
= * 4 /
=N/A%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of 0.00 mean?
Cyduct Diagnostics (CYDX) has a FCF Yield % of 0.00 as of Jun. 30, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Cyduct Diagnostics and its competitors.
Is Cyduct Diagnostics' FCF Yield % too high?
Cyduct Diagnostics' current FCF Yield % is 0.00.
How does Cyduct Diagnostics' FCF Yield % compare to SECI and QTXB?
Cyduct Diagnostics' FCF Yield % of 0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Devices & Instruments company?
A good FCF Yield % depends on the Medical Devices & Instruments industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Cyduct Diagnostics and its competitors. Cyduct Diagnostics's current FCF Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyduct Diagnostics stock overvalued right now?
Cyduct Diagnostics (CYDX) has a current FCF Yield % of 0.00. The current FCF Yield % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Cyduct Diagnostics (CYDX), the current FCF Yield % is 0.00 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cyduct Diagnostics Business Description

Address 1698 Post Road East, Suite 1A, Westport, CT, USA, 06880
Cyduct Diagnostics Inc is a clinical-stage diagnostic company. It focuses on creating and enhancing a portfolio of technologies and assets based on the early assessment and detection of Breast Cancer. Its technology platform of MammoView devices is a single-use, high-margin product that assesses, screens, detects, monitors, and facilitates the treatment of identifiable changes that distinguish variations in breast health. The company markets these products under its Solos Endoscopy brand, along with a line of branded surgical instruments, manufactured by third parties to its design specifications, mainly endoscopes and hand-held surgical instruments for the minimally invasive surgery market.